We are working very closely with the Committee and the FDA on these important issues related to the recent recall of certain McNeil over-the-counter medicines. We look forward to addressing the Committee's questions and concerns. As the FDA has stated, the risk of a serious medical event is remote. The recall was not undertaken on the basis of adverse medical events. McNeil and Johnson & Johnson remain committed to placing consumer safety first and have committed to a number of already-announced actions to begin remediation.
Prior to receiving the Committee's invitation, Mr. Weldon was scheduled for back surgery today, from which he is currently recovering. Johnson & Johnson promptly informed the Committee upon receiving its request that Mr. Weldon would not be able to testify while he recovers from surgery. Consistent with his prior, open public statements about the recall, Mr. Weldon reiterated his willingness to communicate with the Committee after he recovers from surgery. Johnson & Johnson's Worldwide Chairman of the Consumer Group, Colleen Goggins, is prepared to testify at the May 27 hearing.
Health & Wellness
Update on the U.S. House Committee Hearing on the McNeil Consumer Healthcare Recall
Last week, Johnson & Johnson was advised that the U.S. House Committee on Oversight and Government Reform was planning to hold a hearing on May 27th on the recent McNeil Consumer Healthcare recall, at which Chairman and Chief Executive Officer Bill Weldon was invited to provide testimony. There have been some questions from the media about the company’s plans for the hearing, and I thought I’d pass on the statement we’ve been sharing with reporters: